Key insights from therapeutic drug monitoring in Crohn’s disease patients

Margien L. Seinen, Nanne K. de Boer, Adriaan A. van Bodegraven

Research output: Contribution to journalArticleAcademicpeer-review

11 Citations (Scopus)


Introduction: The incidence and prevalence of Crohn’s disease are increasing causing a significant disease burden. Therapeutic drug monitoring (TDM) is advocated as a promising tool for personalized or individual-tailored therapy strategies and has been welcomed as a new means to improve current therapy strategies. Nevertheless, pharmacokinetic-based TDM has limitations, and straightforward target concentrations for most therapies are lacking. Areas covered: In the following concise review of literature, key insights of TDM in thiopurine, methotrexate, anti-TNF, vedolizumab and ustekinumab therapy for Crohn’s disease are being described. Expert opinion: Therapeutic drug monitoring may, up till now, be helpful to adjust thiopurine and infliximab therapy, primarily in a reactive setting, in case of inefficacy and of occurrence of adverse event. With this restricted application, the goal of individualized therapy based on TDM has not yet been achieved.
Original languageEnglish
Pages (from-to)399-406
Number of pages8
JournalExpert Opinion on Drug Metabolism and Toxicology
Issue number5
Publication statusPublished - 4 May 2019


  • Crohn’s disease
  • TPMT
  • anti-TNF
  • methotrexate
  • therapeutic drug monitoring
  • thiopurine
  • ustekinumab
  • vedolizumab

Cite this